EUCTR2013-004671-12-BE进行中（未招募）不适用
Predictive value of biomarkers in patients with amnestic mild cognitive impairment
niversity of Leuven0 个研究点开始时间: 2014年5月20日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient is male or female and between = 55 and = 85 years of age on the day of signing the consent form.
- •2.If female, patient is not of reproductive potential (two years post-menopausal or surgically sterile).
- •4.Patient has a subjective memory concern as reported by subject, study partner, or clinician.
- •5.Patient has an abnormal memory function documented by scoring within the
- •education adjusted ranges on the CANTAB memory performance (= -1SD).
- •6. Patient has a Global Clinical Dementia Rating score of 0 or 0.5.
- •7.In the opinion of the investigator, the patient is in stable medical condition and willing and able to perform study procedures in the opinion of the investigator.
- •8.Patient has at least six years of education, or work history sufficient, in the investigator’s opinion, to exclude mental retardation.
- •9.Patient is fluent in written and verbal Dutch.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Patient has a history or current evidence of a neurological disorder, that in the opinion of the primary investigator may contribute to the subject's cognitive impairment, including, but not limited to:
- •?Large-vessel stroke,
- •?Parkinson’s disease,
- •?progressive supranuclear palsy,
- •?Huntington’s disease,
- •?amyotrophic lateral sclerosis,
- •?multiple sclerosis,
- •?CNS infection,
- •?significant head trauma with loss of consciousness,
- •?Normal pressure hydrocephalus
- •2.Patient has a history of large-vessel stroke or evidence of a large-vessel infarction or other focal lesions on baseline MRI scan that may contribute to the cause of the memory impairment in the opinion of the investigator. Vascular white matter lesions or other signs of microangiopathy will not be considered an exclusion.
- •3.Patient has a history within 6 months prior to screening visit or current evidence of a psychotic disorder or a major untreated depressive disorder.
- •4.Patient has a history of malignancy =5 years prior to signing informed consent, except for patients who have undergone potentially curative therapy with no evidence of recurrence for 1 year, and who are deemed at low risk for recurrence by her/his treating physician.
- •5.Patient has a history or current evidence of any potentially known clinically significant condition , therapy, lab abnormality or other circumstance that in the opinion of the investigator might confound the results of the study, or interfere with the patient’s participation for the full duration of the study, such that it is not in the best interest of the patient to participate.
- •6. Patients currently use specific psychoactive medications (neuroleptics, chronic anxiolytics, tricyclic antidepressants, antiepileptics, anticholinergics etc.). Stable dose trazodone, mirtazapine or low dose benzodiazepines prescribed for mild insomnia is allowed.
- •7. Patients currently use antithrombotics with the exception of acetyl salicylic acid (exclusionary for lumbar puncture).
- •8. Cholinesterase inhibitors are allowable if stable for 12 weeks prior to screen.
- •9. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV
- •10.Patient is currently participating or has participated in a study with an investigational compound or neuropsychological measures within 30 days of signing informed consent.
- •11. Subject has any magnetizable metal prostheses, implants or foreign objects that could pose a hazard during MRI scans.
研究者
相似试验
尚未招募
不适用
Detection of prognostic biomarkers in patients with oral squamous cell carcinoma with tissue microarrayOral Squamous Cell CarcinomaC01C02C03C04C05C06Malignant neoplasm of base of tongueMalignant neoplasm of other and unspecified parts of tongueMalignant neoplasm of gumMalignant neoplasm of floor of mouthMalignant neoplasm of palateMalignant neoplasm of other and unspecified parts of mouthDRKS00010431niversitätsklinikum Hamburg-Eppendorf1,000
招募中
不适用
Prognostic models and biomarkers in patients with acute decompensated heart failure admitted to wardacute decompensated heart failureacute heart failure10019280NL-OMON46619Catharina-ziekenhuis278
尚未招募
不适用
Heart failure on wardHeart failureNL-OMON27799Eigen geïnitieerd onderzoek278
尚未招募
不适用
Phyisician Led CIMAvax-EGF lung biomarkersAdvanced non small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000355Center of Molecular Immunology (CIM)140
尚未招募
不适用
Evaluation of biomolecules to know cancer response in breast cancer patientsCTRI/2022/06/043109ICMR Adhoc extramural grant